Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_683_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

30.08.2026

Размер:

56 Мб

Скачать

☆

<<< < Предыдущая 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 4849 / 5049 50 > Следующая >>>

Pharmacological Pain Management 469

Downloaded from https://onlinelibrary.wiley.com/doi/ by Universität Bern, Wiley Online Library on [22/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

https://t.me/medicina_free

with medications for alcohol dependence, such as naltrexone, nicotine substitution, cognitive therapy, or mindfulness- based therapy [27]. However, even in abstinence from alcohol and smoking, the pain often persists.

Pain treatment should be managed in an interdisciplinary fashion, starting with an open discussion on treatment goals. An alignment of expectations is important, as some patients might expect complete resolution of pain, which is seldom achievable. A psychological evaluation is also essential, as comorbid depression and anxiety can worsen the sensation of pain as pain, anxiety, and depression are neuroanatomically and neurochemically linked [28]. Cognitive therapy can also be used to improve both affective mood disorders and improve pain- coping[29].

Neuromodulation has also been used successfully in treating pancreatic pain by modulating brain plasticity where mechanisms such as hyperpolarization, activation of endogenous opioids, and descending inhibition may also play a role[27,30]. It can suppress activity or promote the facilitation of the targeted area, but highrandomized controlled studies (RCT) are lacking. A small RCT showed that acupuncture was beneficial in CP, but the effect is short- lasting[31]. Pilot studies have shown an effect of transcranial magnetic stimulations and spinal cord stimulation, but studies have lacked a valid placebo arm and as such are subject to major bias[32].

quality

In randomized studies, surgery has proven to be superior to endoscopic treatment [20]. Surgical procedures include resection, either partial or total pancreatectomy, surgical drainage, and combinations. The argument for surgical treatment is that eliminating the source of the nociceptive pain could result in decreased firing from primary afferents and lead to decreased pain[32]. Total pancreatectomy with islet cell transplantation has gained increasing popularity but carries the risk of neuropathic pain development. Furthermore, metabolic consequences can be severe, and technical challenges remain an obstacle[11]. As studies with sham interventions are not possible with pancreatic surgery, controlled studies where patients are followed strictly for several years after surgery are needed, which may identify the role of surgery in CP[32]. However, most series have shown that a significant proportion of the patients still suffer from pain, and therefore pharmacological management is still needed.

The rationale for surgery is also applied when using neuroablative procedures to treat pain. This argument is supported by the fact that local treatments such as neural blocks can alleviate pain in peripheral nerve injury[35]. However, although neural blocks can initially affect pain intensity, studies show that they do not reduce the risk of developing allodynia or hyperalgesia[36], and nerve destruction may, in the long run, worsen neuropathy, and hence pain[30].

Endoscopic andSurgical Pain Treatment

Endoscopic and surgical pain treatment is based on the rationale that pain originates from the pancreas’s structural changes, such as main duct obstruction due to strictures or stones or inflammatory masses in the pancreas. Endoscopic treatment is used in the case of obstruction of the main pancreatic duct, where endoscopic retrograde cholangiopancreatography (ERCP) procedures can maintain drainage from the main pancreatic duct by pancreatic papillotomy, by extraction of pancreatic stones, or temporary stent placement[33]. However, the “plumbing theory” where ductal obstruction is the main cause of pancreatic pain is still debated. Although studies on endoscopic treatments have shown significant improvement in pain intensity in most patients, the studies are biased by several factors, including patient selection, short follow- up period, poor pain assessment methodology, and especially lack of sham control[32]. To circumvent these biases, an ongoing RCT (SCHOKE trial) randomizes patients to either active or sham extracorporeal shock- wave lithotripsy and endoscopic treatment, and currently, 50 patients are enrolled[34].

Pharmacological Pain Management

Simple analgesics are recommended as the first line of treatment in painful CP, especially paracetamol/acetaminophen. Nonsteroidal anti- inflammatory drugs (NSAID) can be used in selected cases but are of limited value due to gastrointestinal toxicity and CP patients’ predisposition for peptic ulcers[27].

Second to simple analgesics is adjuvant therapy consisting mainly of anticonvulsants, antidepressants, and anxiolytics. In the anticonvulsive drug group, only pregabalin has been evaluated in RCT in CP and proven to provide moderate pain relief[37,38]. It has also been shown that pregabalin has inhibitory effects on central sensitization by reducing spreading hyperalgesia[39]. In addition, randomized controlled studies have shown that segmental hyperalgesia is predictive of the analgesic effect of pregabalin in CP [40]. Pregabalin is licensed for neuropathic pain and fibromyalgia but has also been used in other painful conditions with good results[41].

Antidepressants have never been examined as analgesic treatment in CP patients. However, as the noradrenergic system plays an important role in endogenous pain

Follow the

https://t.me/medicina_free

patient

Yes

Pain relief?

Complications:

- Pancreatic

- Extrapancreatic

Treat accordingly

Chronic pancreatic

pain

Simple analgesics

and lifestyle

changes*

Yes

Pain relief?

Yes

Favorable

relationship

between

effect and

side effects

Figure59.1 An example of a mechanism- based treatment algorithm. Simple analgesics include NSAID and paracetamol/acetaminophen; complementary treatments include

acupuncture, vagal nerve stimulations, etc. Pnorepinephrine reuptake inhibitors. *Optimize nutrition and add antioxidants in selected cases, cessation of alcohol and tobacco use.

Consider CBT

or low-dose

opioid treatment

Anticonvulsants

Antidepressants Gabapentinoids

SNRI

abnormalities

or generalized hyperalgesia

Segmental

hyperalgesia

Facilitated

temporal

summation

Deficient

CPM

P-QST

If both QST and psychological evaluation has been

performed, consider short-term opioid therapy or

complementary treatment including neurostimulation

and alternative medications [28]

QST*: quantitative sensory testing; CBT: cognitive behavioral therapy; CPM: conditioned pain modulation; SNRI: serotonin and

Follow the

patient

Psychological

evaluation

abnormalities

Depression/

anxiety

Catastrophizing

P-QST-guided

treatment

Antidepressants

CBT

Favorable

relationship

between

effect and

side effects

Yes

References 471

https://t.me/medicina_free

modulation and antidepressants have proven effective in neuropathic pain[42], the effects may be transferable. It can also be questioned whether RCT in CP patients are needed for all analgesics. Although these patients have many specific features, there is evidence that treatment is likely to be based on the level of the individual rather than at the level of the disease[43]. Hence, data from studies in other pain patients can likely be extrapolated to CP. For example, Arendt- Nielsen and colleagues have shown that the function of the endogenous pain modulatory system predicts the analgesic effect of duloxetine in diabetic neuropathy, and other types of tricyclic antidepressants have been shown to improve the ability to modulate pain[44]. In addition, antidepressants can also be used to treat comorbid depression and anxiety, as the involvement of norepinephrine and serotonin in these diseases can affect pain processing and increase pain sensation.

Although pain management with simple analgesics and adjuvants is preferable, many patients need opioids to dampen their pain. It is necessary to closely monitor patients on opioid treatment, as adverse effects are common and include symptoms such as constipation, nausea, and opioid- induced hyperalgesia, which significantly affect the quality of life; for details, see[45,46]. Furthermore, it is estimated that only about 25% of CP patients benefit from opioid treatment, and it is necessary to evaluate treatment effects often[27]. Tramadol possesses a weak opioid agonist activity and affects the

serotonin- and norepinephrine uptake [47], thereby having a dual- action effect. It is shown to be superior in South African CP patients and has fewer gastrointestinal side effects[48]. However, the results have not been validated in other ethnicities.

In general, the problem with analgesics is not the efficacy but the side effects. It is outside the scope of this chapter to describe the balance between effects and side effects and how to balance between them to the benefit of the patients, but the reader is referred to[49].

In Figure59.1, a proposal for noninvasive treatment of pain in CP is shown.

Conclusion

Pain management remains a challenging and frustrating part of caring for patients with CP, as many issues remain unsolved.

Treatment has to be tailored to the individual, and successful pain management begins with good communication, where it is important to agree upon treatment goals early in the process. The analgesic strategy is multimodal and may include invasive treatments, medical treatments, and adjuvant treatments, bearing in mind that pain in CP is a combination of nociceptive and neuropathic/neuroplastic pain.

References

1 Ammann R, Akovbiantz A, Largiader F, Schueler G. Course

and outcome of chronic pancreatitis. Longitudinal study of a mixed medicalGastroenterology 1984;86(5 Pt 1):820–828.

2 Lankisch PG, Löhr- Happe A, Otto J, Creutzfeldt W.

Natural course in chronic pancreatitis: pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion 1993;54(3):148–155.

3 Lieb JG, Forsmark CE. Pain and chronic pancreatitis.

Aliment Pharmacol Ther 2009;29(7):706–719.

4 Ammann RW, Muellhaupt B. The natural history of pain in

alcoholic chronic pancreatitis. Gastroenterology 1999;116(5):1132–1140.

5 Kempeneers MA, Issa Y, Verdonk RC, Bruno M, Fockens P, Goor

H van et al. Pain patterns in chronic pancreatitis: a nationwide longitudinal cohort study. Gut 2021;70(9):1724–1733.

6 Beyer G, Mahajan UM, Budde C etal. Development and

validation of a chronic pancreatitis prognosis score in 2independent cohorts. Gastroenterology 2017;153(6): 1544–1554.

7 Olesen SS, Juel J, Nielsen AK, Frøkjær JB, Wilder- Smith

OHG, Drewes AM. Pain severity reduces life quality in

surgical series of 245 patients.

chronic pancreatitis: implications for design of future outcome trials. Pancreatology 2014;14(6):497–502.

8 Anaparthy R, Pasricha PJ. Pain and chronic pancreatitis:

is it the plumbing or the wiring? Curr Gastroenterol Rep 2008;10(2):101–106.

9 Olesen SS, Kuhlmann L, Novovic S etal. Association of

multiple patient and disease characteristics with the presence and type of pain in chronic pancreatitis. JGastroenterol Hepatol 2020;35(2):326–333.

10 Sinha A, Patel YA, Cruise M etal. Predictors of post-

operative pain relief in patients with chronic pancreatitis undergoing the Frey or Whipple procedure. J Gastrointest Surg 2016;20(4):734–740.

11 Pasricha PJ. Unraveling the mystery of pain in chronic

pancreatitis. Nat Rev Gastroenterol Hepatol 2012;9(3):140–151.

12 Bockman DE, Buchler M, Malfertheiner P, Beger HG.

Analysis of nerves in chronic pancreatitis. Gastroenterology 1988;94(6):1459–1469.

13 Ceyhan GO, Michalski CW, Demir IE, Müller MW, Friess

H. Pancreatic pain. Best Pract Res Clin Gastroenterol 2008;22(1):31–44.

Pain Management inChronic Pancreatitis

https://t.me/medicina_free

472

14 Drewes AM, Bellin MD, Besselink MG etal. Assessment

of pain associated with chronic pancreatitis: an international consensus guideline. Pancreatology 2021;21(7):1256–1284.

15 Walia A, Hadlandsmyth K, Rastogi R. Individual

differences in affective, cognitive and behavioral components of pain. In: Abd-

Elsayed, ed. Pain: A Review

Guide. Cham: Springer, 2019: 349–352.

16 Drewes AM. Understanding and treatment of chronic

pancreatitis. World J Gastroenterol 2013;19(42): 7219–7221.

17 Turk DC, Dworkin RH, Allen RR etal. Core outcome

domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106(3):337–345.

18 Teo K, Johnson MH, Truter S, Pandanaboyana S, Windsor

JA. Pain assessment in chronic pancreatitis: a comparative review of methods. Pancreatology 2016;16(6):931–939.

Bloechle C, Izbicki JR, Knoefel WT, Kuechler T, Broelsch

CE. Quality of life in chronic pancreatitis, results after duodenum- preserving resection of the head of the pancreas. Pancreas 1995;11(1):77–85.

20 Issa Y, Kempeneers MA, Bruno MJ etal. Effect of early

surgery vs endoscopy-

first approach on pain in patients with chronic pancreatitis: the ESCAPE randomized clinical trial. JAMA 2020;323(3):237–247.

21 Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR,

Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20(5):309–318.

22 Teo K, Johnson MH, Drewes AM, Windsor JA. A

comprehensive pain assessment tool (COMPAT) for chronic pancreatitis: development, face validation and pilot evaluation. Pancreatology 2017;17(5):706–719.

23 Kuhlmann L, Teo K, Olesen SS, Phillips AE, Faghih M,

Tuck N et al. Development of the Comprehensive Pain Assessment Tool Short Form for Chronic Pancreatitis: Validity and Reliability Testing. Clin Gastroenterol Hepatol 2022;20(4):e770– e783.

24 Fayers P, Bottomley A. Quality of life research within the

EORTC—

the EORTC QLQ- C30. Eur J Cancer 2002;

38(Suppl 4):125–133.

25 Phillips AE, Faghih M, Kuhlmann L etal. A clinically

feasible method for the assessment and characterization of pain in patients with chronic pancreatitis: pain phenotyping in chronic pancreatitis. Pancreatology 2020;20(1):25–34.

26 Faghih M, Phillips AE, Kuhlmann L, Afghani E, Drewes

AM, Yadav D et al. Pancreatic QST Differentiates Chronic Pancreatitis Patients into Distinct Pain Phenotypes Independent of Psychiatric Comorbidities. Clin Gastroenterol Hepatol. 2022; 20(1):153–161.e2.

27 Drewes AM, Bouwense SAW, Campbell CM etal.

Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology 2017;17(5):720–731.

28 Surah A, Baranidharan G, Morley S. Chronic pain and

depression. Contin Educ Anaesthesia Crit Care Pain 2014;14(2):85–89.

29 Ashburn MA, Staats PS. Management of chronic pain.

Lancet 1999;353(9167):1865–1869.

30 Fregni F, Pascual- Leone A, Freedman SD. Pain in chronic

pancreatitis: a salutogenic mechanism or a maladaptive brain response? Pancreatology 2007;7:411–422.

31 Juel J, Liguori S, Liguori A etal. Acupuncture for pain in

chronic pancreatitis: a single-

blinded randomized

crossover trial. Pancreas 2017;46(2):170–176.

32 Drewes AM, Kempeneers MA, Andersen DK etal.

Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons! Gut 2019;68(8):1343–1351.

33 Rösch T, Daniel S, Scholz M etal. Endoscopic treatment of

chronic pancreatitis: a multicenter study of 1000 patients with long- term follow- up. Endoscopy 2002;34(10):765–771.

34 Olesen SS, Drewes AM, Gaud R etal. Combined

extracorporeal shock wave lithotripsy and endoscopic treatment for pain in chronic pancreatitis (SCHOKE trial): study protocol for a randomized, sham-

controlled

trial. Trials 2020;21(1):1–9.

35 Vaso A, Adahan HM, Gjika A etal. Peripheral nervous

system origin of phantom limb pain. Pain 2014;155(7):1384–1391.

36 Suter MR, Papaloïzos M, Berde CB etal. Development of

neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology 2003;99(6):1402–1408.

37 Olesen SS, Bouwense SAW, Wildersmith OHG, Van Goor

H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 2011;141(2):536–543.

38 Talukdar R, Lakhtakia S, Reddy DN etal. Antioxidant

cocktail and pregabalin combination ameliorates pain recurrence after ductal clearance in chronic pancreatitis: results of a randomized, double blind, placebo-

controlled

trial. J Gastroenterol Hepatol 2016;31(9):1654–1662.

39 Bouwense SA, Olesen SS, Drewes AM, Poley J- W, van

Goor H, Wilder- Smith OHG. Effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial. PLoS ONE 2012;7(8):e42096.

40 Olesen SS, Graversen C, Bouwense SAW, van Goor H,

Wilder- Smith OHG, Drewes AM. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS ONE 2013;8(3):e57963.

41 Gajraj NM. Pregabalin: its pharmacology and use in pain

management. Anesth Analg 2007;105(6):1805–1815.

42 Dharmshaktu P, Tayal V, Kalra BS. Efficacy of

antidepressants as analgesics: a review. J Clin Pharmacol 2012;52(1):6–17.

43 Edwards RR, Dworkin RH, Turk DC etal. Patient

phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 2016;157(9).

References 473

https://t.me/medicina_free

44 Yarnitsky D, Granot M, Nahman- Averbuch H, Khamaisi

M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153(6):1193–1198.

45 Häuser W, Morlion B, Vowles KE etal. European clinical

practice recommendations on opioids for chronic noncancer pain– Part 1: Role of opioids in the management of chronic noncancer pain. Eur J Pain 2021;25(5):949–968.

46 Krčevski Škvarč N, Morlion B, Vowles KE etal. European

clinical practice recommendations on opioids for chronic noncancer pain– Part 2: Special situations. Eur J Pain 2021;25(5):969–985.

47 Olesen SS, Juel J, Graversen C, Kolesnikov Y, Wilder-

Smith OHG, Drewes AM. Pharmacological pain management in chronic pancreatitis. World J Gastroenterol 2013;19(42):7292–7301.

48 Wilder- Smith CH, Hill L, Oshir W, O’Keefe S. Effect of

tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999;44(6):1107–1116.

49 Andresen T, Niesters M, Dahan A, Morlion B, O’Brien T,

Drewes AM. Pharmacological management of chronic pain: how to deal with the Catch-

22 situation. J Curr Med

Res Opin 2021;4(2).

474

https://t.me/medicina_free

Adjunctive Therapy inChronic Pancreatitis

Anna Evans Phillips MD, MS

Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Introduction

Chronic pancreatitis (CP) is a progressive fibroinflammatory disease of the pancreas for which there is no cure. Therapies in CP are directed at managing symptoms of the disease, mainly the dominant symptom of abdominal pain. Patients with evidence of pancreatic ductal obstruction are often managed with endoscopic or surgical therapy to relieve obstruction in addition to analgesia, whereas patients without clear signs of ductal obstruction are managed medically. The foundation of medical management consists of analgesic therapy, including both opioids and non- opioid analgesics. Adjunctive therapies are used to address pain by targeting mechanisms of pain that differ from traditional analgesia, as well as treating concomitant affective disorders, digestive disorders, and malnutrition. Pain treatment studies in CP are difficult to compare as endpoints vary widely between studies; however, the clinical need for pain treatment in this population persists and requires creativity and open- mindedness on the part of healthcare providers [1]. This chapter will review adjunctive therapies in CP, which are meant to serve as complementary therapies addressing pain or CP sequelae that are inadequately treated by traditional analgesia or interventions.

Therapies forAffective Disorders

Pain- related factors in CP including anxiety and depression can overlap and have a cumulatively detrimental effect on patients with CP[2]. Affective psychiatric disorders including anxiety and depression are highly prevalent in patients with CP, and frequently coexist[3]. In a cross- sectional analysis of an international cohort of CP

patients, the prevalence of anxiety or depression symptoms was seen to be 46.8% and 38.6%, respectively, and their presence was associated with increased severity of pain and interference of pain with daily living[3]. The presence of depression in this study was independently associated with decreased quality of life, further highlighting the impact that psychiatric comorbidity can have in this patient population[3]. Assessment for and treatment of affective disorders concomitant with CP should be a high priority in clinical practice and symptoms can be detected effectively with questionnaire screening instruments.

Antidepressant Medications

Medical therapy for affective disorders including tricyclic antidepressants (TCA), selective serotonin uptake inhibitors (SSRI), and serotonin noradrenergic reuptake inhibitors (SNRI) have been recommended by clinical guidelines for treatment of painful CP as part of a multifaceted approach to therapy due to their analgesic effects (SNRI and TCA) and effect on concomitant depression (all three) [1]. Although they may be used in clinical practice, there is little data on the prevalence of their use or their effects in this population. The North American Pancreatitis Study 2 (NAPS2) group assessed the association between constant severe pain and genetic loci for depression and noted that 56% of that population selfreported taking an SSRI when asked for current medications [4]. There is much evidence for neuropathy in CP[5]. Multiple studies have been conducted to assess the efficacy of duloxetine, an SNRI, at treating neuropathic pain in diabetic neuropathy, fibromyalgia, and pain associated with depression, prompting a Cochrane review in 2009 and subsequent update in 2014 [6,7]. Together, the studies showed that duloxetine is effective

The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery, Fourth Edition. Edited by Hans G. Beger, Markus W. Büchler, RalphH. Hruban, Julia Mayerle, John P. Neoptolemos, Tooru Shimosegawa, Andrew L. Warshaw, David C. Whitcomb, and Yupei Zhao. © 2023 John Wiley & Sons Ltd. Published 2023 by John Wiley & Sons Ltd. Companion website: www.wiley.com/go/beger/thepancreas4e

Treatments forNeuropathy 475

https://t.me/medicina_free

in reducing pain in diabetic neuropathy, as well as for pain symptoms of depression. The direct analgesic effect of duloxetine is considered to be independent of the drug’s effect on depression symptoms [8], making it particularly relevant in patients with painful CP and concomitant depression. Studies in other chronic pain conditions have shown antidepressant medications broadly to have varying degrees of direct analgesia, with SSRI medications being the least analgesic but having a more acceptable tolerance profile than others[9]. While these results may be extrapolated to subgroups within the CP population, it is noted that no clinical trials have evaluated the effect of SSRI or other antidepressant medications in CP patients specifically.

Psychosocial Therapies

When regarded through the lens of the biopsychosocial model of illness, painful CP is understood as a complex phenomenon where pain, quality of life, stigma, selfblame, and addictive behaviors (for a subset of patients) impact and often exacerbate one another [10]. Psychologic therapies including mindfulness therapy and cognitive behavioral therapy are important tools to impact these forces individually. Combining any such therapies with interventions intended to address addictive behaviors including alcohol- , tobacco- , or opioiduse disorders is a priority in this population as the first two are independent risk factors for progression of CP and all can exacerbate or amplify the pain experience.

Mindfulness therapy, a talk therapy often linked to Buddhism, encourages patients to focus nonjudgmentally on the present lived experience and teaches coping mechanisms for dealing with challenges including stress and pain. In a pilot study of 10 CP patients with pain compared with 5 healthy controls, a 28- day telephonebased mindfulness therapy intervention was completed, showing improvement in social aspects of quality of life as measured by the SF- 36[11]. While there was no significant improvement in physical quality of life, and the study was limited by small sample size and a broad definition of CP, the effort did establish feasibility of such an intervention and illustrates the potential impact this could have for CP patients suffering from poor quality oflife.

Cognitive behavioral therapy (CBT), a psychosocial intervention aiming to challenge cognitive distortions and improve emotional regulation and coping, has also previously been tested in an internet- based randomized, controlled pilot trial of 30 subjects with painful CP[12]. Not only was the intervention deemed feasible and acceptable, but the proportion of those who responded with reduced pain intensity and pain interference at 3months was significantly greater in the internet- based

CBT group than the control group. Psychological therapies show significant promise in CP patients with pain who are suffering from concomitant psychiatric illness and should be strongly considered in this patient subpopulation.

Although published literature on these types of interventions remains rare, patients who are suffering from painful CP and additional psychiatric illness may strongly benefit from referral to expert providers of psychosocial therapies, and there is at least some evidence that they are effective.

Treatments forNeuropathy

Neuropathy is an additional contributor to the experience of many patients with CP, and pain related to this can be particularly challenging to treat[5]. Alterations in pain processing due to changes in the nerves themselves or in patterns of transmission of pain signals can result in pain that is resistant to traditional analgesia.

Medications

Pregabalin, a lipophilic analog to the inhibitory neurotransmitter gamma- aminobutyric acid (GABA), has been approved by the US Food and Drug Administration for treatment of neuropathic pain and may have a role in treatment of painful CP. Pregabalin has previously been shown to reduce the pain intensity of patients with CP in a randomized, double- blind, placebo- controlled trial of 64 patients after 3weeks compared to placebo[13]. In a separate placebo- controlled randomized trial of 90 patients, those who received a combination of antioxidant therapy and pregabalin were shown to have significant reduction in pain intensity, non- opioid analgesic requirement, and hospital admissions for pain during the 12- week study period compared to those who received placebo [14]. A randomized, double- blind, placebocontrolled study of 88 patients with recurrent pain following pancreatic ductal clearance additionally showed significant reduction of pain intensity after 8 weeks of therapy in those who received antioxidants and pregabalin compared with placebo [15]. It is noted that in the study from Sureshkumar etal. [13], patients with concomitant major depression, and those with intractable pain who had previously failed medical management were excluded, and in the study from Talukdar etal.[14], patients who had received high- potency narcotics were excluded. Given the prevalence of major depression and narcotic use among CP patients, these results are potentially difficult to extrapolate to the broader CP population. Additional neuromodulators including olanzapine, quetiapine, ketamine, and others may have effect in CP

Adjunctive Therapy inChronic Pancreatitis

https://t.me/medicina_free

476

pain though they have not been specifically studied in this population. The role of neuropathic agents is additionally discussed in the chapter on pain management, and the role of antioxidant therapy is further discussed in a dedicated chapter in this text.

Nerve Blocks

Blockade of specific nerves or nerve groups has been attempted for painful CP with varying degrees of success. Celiac plexus blockade is a technique performed via radiographic, CT- guided, or endoscopic- guided approaches in which steroids and local anesthetic are injected at the celiac plexus[16]. Response rates following therapy vary across studies but in general are lower than 60% [17,18]. The duration of response is only approximately 3–6months, making this more of a temporizing measure than a treatment from which durable pain response is expected. Importantly, the risk of nerve damage associated with the procedure may actually worsen neuropathy, leading some to consider this treatment obsolete in painful pancreatic disease that is nonmalignant[19].

A small study of subcostal transversus abdominis plane blockade has shown reduction in pain from myofascial pain syndrome associated with CP[20]. This study was limited by the fact that the technique is ineffective for visceral pain as well as for pain from ongoing pancreatic inflammation: there was additionally no control arm making the results less robust. A single-

blinded randomized crossover trial of acupuncture did show pain relief from treatment as compared to sham, but the effect was short- lived and disappeared after one week [21]. Several other small studies have shown some degree of benefit in research settings from experimental interventions including cervical transcutaneous neuromodulation, and transcranial magnetic stimulation[22,23]. The potential for clinical use of these techniques are limited by the fact that they are often administered only in research settings, require specific expertise, have shortlived effects, and are not widely available.

Central Sensitization

Central sensitization, a phenomenon of altered processing of nociception, has been described in patients with painful CP and is thought to be a critical aspect of the pain experience in this disease[24]. The presence of central sensitization has the potential to render traditional therapies such as decompression of an obstructed pancreatic duct or surgical drainage procedures ineffective in providing pain relief[25]. Techniques to reliably identify patterns of central sensitization including manifestations of widespread hyperalgesia or altered central pain

modulation have previously been only available in research settings; however, a bedside technique intended for clinical adaptation has been recently developed[26]. Pancreatic quantitative sensory testing (P-

QST) differentiates CP patients into distinct phenotypes by characterizing their nociceptive patterns and identifies patients with characteristics of central sensitization[27]. There is no treatment for central sensitization; however, both pregabalin and S- ketamine have shown promise in initial trials in modulating measures of hyperalgesia[28–30]. A randomized trial of S- ketamine treatment has been proposed but not yet completed[31].

Therapy forNutritional Disorders

Malnutrition is a frequent complication of CP due to exocrine pancreatic insufficiency (EPI) and maldigestion[32]. This can be further exacerbated by concomitant disorders of delayed gastric transit, small intestinal bacterial overgrowth (SIBO), and sarcopenia [33–36]. While nutritional evaluation of CP is covered elsewhere in this text in detail, diagnosis of concomitant gastrointestinal disorders, vitamin and mineral deficiencies, and their treatment or supplementation may be effective adjuncts in the treatment of CP. Delayed intestinal transit, bloating from fat malabsorption, and neuropathy due to underlying vitamin deficiency are all possible sources of pain in CP complicated by malnutrition [37]. Diagnostic testing to include anthropometric, biochemical, and clinical markers of malnutrition for those patients at high risk on an annual basis have been recommended as a means of identifying those patients with possible vitamin and mineral deficiencies complicating their underlying CP[37].

Pancreatic Enzyme Replacement Therapy

Pancreatic enzyme replacement therapy (PERT) is designed to assist with the absorption of fat, protein, and micronutrients in EPI. Pain reduction from PERT is mostly secondary to decreased symptoms of maldigestion including hypermotility of the colon in the setting of steatorrhea, though some contribution from suppression of pancreatic enzyme release may be possible[38,39]. In a large systematic review and meta- analysis of clinical trials PERT has been shown to improve fat absorption in patients with CP both compared to patient baseline levels and compared to therapy with placebo[40]. In the same study, PERT was also shown to improve abdominal pain without significant adverse events. The perceived efficacy of PERT (by patients) for treatment of pain in CP in the absence of EPI was found to be low (36.3%); perceived efficacy of PERT rose only to 50% in patients with

References 477

https://t.me/medicina_free

both EPI and pain [41]. High- quality large rigorous studies on the efficacy of PERT for malnutrition in CP are needed, as is more consistent education for practitioners regarding indications for PERT therapy and potential benefit. Evaluation of an insured US population showed that both testing for EPI and adequate dosing of prescribed PERT were infrequent and inconsistent, suggesting that this therapy is underutilized and used in a suboptimal fashion in CP patients overall[42].

Vitamins, Antioxidants, andOctreotide

Fat- soluble vitamin levels are a frequent concern in patients with CP, especially in patients with symptoms of fat malabsorption. Vitamin D deficiency is the most common fat- soluble vitamin deficiency in CP patients (>50%), though it also common in patients without CP[32]. Vitamin A and E deficiencies have been seen in approximately 15% and 25% of CP patients, respectively [32]. Supplementation of fat- soluble vitamins is recommended to avoid the potentially serious complications of prolonged or severe deficiency including night blindness (vitamin A), neuropathy (vitamin E), and mineral bone disease such as osteopenia or osteoporosis (vitamin D). In particular, the prevalence of osteopathy in CP patients has been found to be significantly higher than that of the general population, and assessment and treatment has been recommended as part of routine care[43–45]. Diagnosis and supplementation of watersoluble vitamin and micronutrient deficiencies in patients with poor diet or other markers of malnutrition are also recommended.

Indications for, efficacy of, and evidence regarding antioxidant use is reviewed in a separate chapter, but they are mentioned here as part of the adjunctive armamentarium for painful CP, through reduction of acinar cell injury by protecting against oxidative stress[41]. It is noted that their use is infrequent and dosing is quite varied across practitioners, and reported data has been highly variable on their efficacy [41,46,47]. Similarly, octroeotide—

a synthetic somatostatin analog that has an inhibitory effect on pancreatic secretion— has been utilized to decrease pancreatic stimulation and release of enzymes. Its use in CP has been infrequent, and the

reported efficacy for symptoms of CP has been highly variable[41].

Cannabinoids

Reported cannabinoid use has increased in recent years as an analgesic agent for patients with painful CP concomitant with the spread of medically directed marijuana therapies, though high- quality randomized study data is scarce and cannabinoids represent a heterogenous group of chemical substances[48]. Delta- 9 tetrahydrocannabinol (THC), the most abundant cannabinoid in the plant, was tested in a phase- 2 placebo- controlled clinical trial of patients with chronic abdominal pain, but unfortunately did not show any significant improvement compared to placebo[49]. This study was notably limited by heterogeneity of the etiology of abdominal pain in the studied patients, with CP and post- surgical patients combined into a single group. A separate small study was not designed to evaluate pain response to cannabis, but detected a reduction in opioid use, hospitalizations, and emergency room visits for CP patients after their enrollment in a state- directed therapeutic cannabis program compared to before their enrollment in the program[50]. A recent observational study shows that medical marijuana is used more frequently in patients maintained on chronic opioid therapy than those who are not on chronic opioids, suggesting that its utility is mainly seen as an adjunctive agent in this patient population[51].

Conclusions

Adjunctive therapies in CP are initiated because existing analgesic and interventional therapies result in suboptimal relief of symptoms for this disease. A thorough evaluation for concomitant and complicating disorders should be conducted, and directed adjunctive agents can be initiated based on the individual patient situation after traditional therapies for CP have been optimized. The evidence for the efficacy of adjunctive therapies in CP remains quite limited even though there are hints that they can form part of an overall treatment regime for painful CP.

References

1 Drewes AM, van Veldhuisen CL, Bellin MD etal.

Assessment of pain associated with chronic pancreatitis: an international consensus guideline. Pancreatology 2021;21(7):1256–1284.

2 Olesen SS, Phillips AE, Faghih M etal. Overlap and cumulative

effects of pancreatic duct obstruction, abnormal pain processing and psychological distress on patient- reported outcomes in chronic pancreatitis. Gut2022;71(12):2518–2525.

Adjunctive Therapy inChronic Pancreatitis

https://t.me/medicina_free

478

3 Phillips AE, Faghih M, Drewes AM, Singh VK, Yadav D,

Olesen SS. Psychiatric comorbidity in patients with chronic pancreatitis associates with pain and reduced quality of life. Am J Gastroenterol 2020;115(12):2077–2085.

4 Dunbar E, Greer PJ, Melhem N etal. Constant- severe pain

in chronic pancreatitis is associated with genetic loci for major depression in the NAPS2 cohort. J Gastroenterol 2020;55(10):1000–1009.

5 Drewes AM, Krarup AL, Detlefsen S, Malmstrom ML,

Dimcevski G, Funch-

Jensen P. Pain in chronic pancreatitis: the role of neuropathic pain mechanisms. Gut 2008;57(11):1616–1627.

6 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating

painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009(4):CD007115.

7 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating

painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014(1):CD007115.

8 Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of

duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21(6):311–317.

9 Dharmshaktu P, Tayal V, Kalra BS. Efficacy of

antidepressants as analgesics: a review. J Clin Pharmacol 2012;52(1):6–17.

10 Keller CE, Wilcox CM, Gudleski GD, Branham S, Lackner

JM. Beyond abdominal pain: pain beliefs, pain affect, and distress as determinants of quality of life in patients with chronic pancreatitis. J Clin Gastroenterol 2018;52(6):563–568.

11 Aivaliotis VI, Lee Y, Zia J, Wassef W, Abramson M, Park

W. Telephone-

based mindfulness therapy intervention forpatients with chronic pancreatitis. Dig Dis Sci 2017;62(2):502–509.

12 Palermo TM, Law EF, Topazian MD etal. Internet

cognitive-

behavioral therapy for painful chronic pancreatitis: a pilot feasibility randomized controlled trial. Clin Transl Gastroenterol 2021;12(6):e00373.

13 Olesen SS, Bouwense SA, Wilder- Smith OH, van Goor H,

Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 2011;141(2):536–543.

14 Sureshkumar S, Omang A, Anandhi A etal. Efficacy of

pregabalin and antioxidants combination in reducing pain in chronic pancreatitis: a double blind randomized trial. Dig Dis Sci 2021;66(11):4017–4025.

15 Talukdar R, Lakhtakia S, Nageshwar Reddy D etal.

Ameliorating effect of antioxidants and pregabalin combination in pain recurrence after ductal clearance in chronic pancreatitis: results of a randomized, double blind, placebo-

controlled trial. J Gastroenterol Hepatol

2016;31(9):1654–1662.

16 Sachdev AH, Gress FG. Celiac plexus block and neurolysis:

a review. Gastrointest Endosc Clin N Am 2018;28(4):579–586.

17 Gress F, Schmitt C, Sherman S, Ikenberry S, Lehman G.

Aprospective randomized comparison of endoscopic ultrasound- and computed tomography- guided celiac

plexus block for managing chronic pancreatitis pain. AmJGastroenterol 1999;94(4):900–905.

18 LeBlanc JK, DeWitt J, Johnson C etal. A prospective

randomized trial of 1 versus 2injections during EUSguided celiac plexus block for chronic pancreatitis pain. Gastrointest Endosc 2009;69(4):835–842.

19 Drewes AM, Kempeneers MA, Andersen DK etal.

Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons! Gut 2019;68(8):1343–1351.

20 Niraj G, Kamel Y. Ultrasound- guided subcostal tap block

with depot steroids in the management of chronic abdominal pain secondary to chronic pancreatitis: a three-

year prospective audit in 54 patients. Pain Med

2020;21(1):118–124.

21 Juel J, Liguori S, Liguori A etal. Acupuncture for pain

inchronic pancreatitis: a single-

blinded randomized

crossover trial. Pancreas 2017;46(2):170–176.

22 Muthulingam JA, Olesen SS, Hansen TM, Brock C,

Drewes AM, Frokjaer JB. Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: a randomised sham controlled clinical trial. PLoS ONE 2021;16(2):e0247653.

23 Fregni F, Potvin K, Dasilva D etal. Clinical effects and

brain metabolic correlates in non-

invasive cortical neuromodulation for visceral pain. Eur J Pain 2011;15(1):53–60.

24 Bouwense SA, Olesen SS, Drewes AM, Frokjaer JB, van

Goor H, Wilder-

Smith OH. Is altered central pain processing related to disease stage in chronic pancreatitis patients with pain? An exploratory study. PLoS ONE 2013;8(2):e55460.

25 Bouwense SA, Buscher HC, van Goor H, Wilder- Smith

OH. Has central sensitization become independent of nociceptive input in chronic pancreatitis patients who fail thoracoscopic splanchnicectomy? Reg Anesth Pain Med 2011;36(6):531–536.

26 Phillips AE, Faghih M, Kuhlmann L etal. A clinically

feasible method for the assessment and characterization of pain in patients with chronic pancreatitis. Pancreatology 2020;20(1):25–34.

27 Faghih M, Phillips AE, Kuhlmann L etal. Pancreatic QST

differentiates chronic pancreatitis patients into distinct pain phenotypes independent of psychiatric comorbidities. Clin Gastroenterol Hepatol 2022;20(1):153–161.e2.

28 Bouwense SA, Olesen SS, Drewes AM, Poley JW, van Goor

H, Wilder- Smith OH. Effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial. PLoS ONE 2012;7(8):e42096.

29 Bouwense SA, Buscher HC, van Goor H, Wilder- Smith

OH. S- ketamine modulates hyperalgesia in patients with chronic pancreatitis pain. Reg Anesth Pain Med 2011;36(3):303–307.

30 Arendt- Nielsen L, Mansikka H, Staahl C etal.

Atranslational study of the effects of ketamine and pregabalin on temporal summation of experimental pain. Reg Anesth Pain Med 2011;36(6):585–591.

<<< < Предыдущая 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 4849 / 5049 50 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
30.08.202657 Мб0Книга_677_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202657 Мб0Книга_678_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202657 Мб0Книга_680_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_681_Библиотеки_им_академика_М_И_Перельмана.epub
#
30.08.202656 Мб0Книга_682_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_683_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_684_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_685_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_686_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202656 Мб0Книга_688_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202655 Мб0Книга_689_Библиотеки_им_академика_М_И_Перельмана.pdf